Preparation
Abstract must be submitted online.
The abstract must be in English.
There is no limit to the number of abstracts submitted.
The size limit for the abstract (including title, body and tables) is 3400 characters. This does not include spaces.
Please see the submissions website for specific details regarding the inclusion of tables. Tables count for 320 characters.
Figures cannot be included in an abstract.
Any author who cannot present on a particular day of the week must provide that information by emailing sabcs@uthscsa.edu.
Submitting an abstract online does not register you to attend the Symposium. To register for the Symposium, please click here.
Submission Fee
Include a payment of $50.00 for each abstract submitted.
A credit card payment is required.
The abstract fee is not refundable.
Abstracts are due by July 15, 2022.
Submission
Abstracts must be submitted online.
When finished with your online submission, be sure to submit payment. Click the "Submit" button. Abstracts received without a properly completed Financial Disclosure Declaration will not be considered. The size limit for the abstract (including title, body, and tables) is 3400 characters - this does not include spaces. Please see the submissions website for specific details regarding tables.
Any author who cannot present on a particular day of the week must provide that information by emailing sabcs@uthscsa.edu by August 15, 2022.
Abstracts are due by July 15, 2022.
Abstract Subject Categories
The subject categories for abstract submission are listed below. You must select the most appropriate category for your abstract and insert its corresponding number in the box on the abstract form. Please be aware that the Symposium Abstract Review Committee may re-categorize your abstract if doing so is deemed appropriate.
Subject Categories List
DETECTION/DIAGNOSIS
Axillary Nodes
101. Axillary Staging and Sentinel Nodes
Pathology
102. Diagnostic Pathology
104. Circulating Biomarkers and ctDNA
105. Circulating Tumor Cells
106. Micrometastases
Imaging and Screening
107. Breast Imaging - Mammography etc.
110. Molecular, Functional, and Novel Imaging
111. Radiology - Tumor Monitoring
112. Screening
Other
113. Detection/Diagnosis - Other
TUMOR CELL AND MOLECULAR BIOLOGY
202. Animal Models
203. Ex vivo Models
205. Cell Cycle Regulation
206. Cellular Mechanisms
207. DNA Damage and Repair
208. Drug Resistance
209. Endocrine Therapy and Resistance
210. Epigenetics
211. Epithelial-Mesenchymal Transition
212. Etiology/Carcinogenesis
213. Gene Therapy
214. Genetics - Germline Changes
215. Genetics - Somatic Changes
216. Genomics
217. Growth Factors
218. Hormonal Factors and Receptors
219. Immunology and Preclinical Immunotherapy
220. Mammary Development and Differentiation
221. Metabolism and Breast Cancer
222. Microenvironment; Stromal - Epithelial Interactions
223. MicroRNAs and Other Non-coding RNAs
224. Molecular Profiles
225. New Drugs and Mechanisms
226. Novel/Emerging Therapeutic Targets
227. Oncogenes/Tumor Suppressor Genes
228. Signaling Pathways
229. Stem/Progenitor Cells
232. Tumor Heterogeneity/Molecular Subclassification
233. Tumor Progression, Invasion, and Metastasis
235. Tumor Cell and Molecular Biology - Other
PROGNOSTIC AND PREDICTIVE FACTORS
Biomarkers Predicting Treatment Response
301. Predictive Biomarkers for Chemotherapies
302. Predictive Biomarkers for Endocrine Therapies
303. Predictive Biomarkers for Targeted Therapies
304. Predictive Biomarkers for Combined Modality Therapies
305. Predictive Biomarkers – Other
Prognosis – Biomarkers of Natural History
306. Prognostic Factors - Clinical Testing and Validation
307. Prognostic Factors - Index Scores
308. Prognostic Factors - Other
EPIDEMIOLOGY, RISK, AND PREVENTION
401. Epidemiology - Population Studies
402. Epidemiology - Genetic and Molecular
403. Ethnic/Racial Aspects
404. Familial Breast Cancer; Genetic Testing
406. Prevention - Behavioral Interventions
407. Prevention - Nutritional Studies
408. Prevention - Clinical Trials
409. Prevention - Preclinical Studies and Model Systems
410. Risk Factors and Modeling
411. Epidemiology, Risk, and Prevention - Other
PSYCHOSOCIAL, QUALITY OF LIFE, AND EDUCATIONAL ASPECTS
Social and Education Issues
501. Advocacy
502. Cost-Effectiveness
503. Disparities and Barriers to Care
504. Doctor-Patient Communication
505. Education
Quality of Life Issues
506. Palliation and Pain Management
507. Psychosocial Aspects
508. Quality of Life - Supportive Care
509. Survivorship Research
Other
510. Psychosocial, QOL, and Educational Aspects - Other
TREATMENT
Adjuvant Therapy
601. Adjuvant Chemotherapy
602. Adjuvant Endocrine Therapy
603. Adjuvant Therapy - Targeted
604. Adjuvant Therapy - Other
Advanced Disease Treatment
605. Advanced Chemotherapy
606. Advanced Endocrine Therapy
607. Advanced Therapy - Targeted
608. Advanced Therapy - Other
Surgery and Radiotherapy
609. Breast Conservation
610. Radiotherapy
611. Surgery
612. Reconstruction
Therapeutic Strategies
613. Neoadjuvant Chemotherapy
614. Neoadjuvant Endocrine Therapy
616. Antiangiogenic Therapy (Adjuvant and Metastatic)
619. HER2-Targeted Therapy
620. Immunotherapy (Clinical)
621. New Drugs and Treatment Strategies
622. Novel Targets and Targeted Agents
624. Toxicities - Management
Types and Sites of Breast Cancer
625. Bone Metastases
626. Brain Metastases
627. DCIS/LCIS
628. Male Breast Cancer
629. Inflammatory Breast Cancer
Research Resources
630. Patient Resources
631. Tissue and Data Banks
632. Clinical Trials Design and Management
Other
633. Treatment - Other
ONGOING CLINICAL TRIALS
701. Ongoing Clinical Trials (see rules below)
This category is for work that is ongoing. It is to inform and inspire, and/or to invite the collaboration of others. It is to not to discuss the trial results, either preliminary or formally completed - presentations with this type of information should be submitted as regular abstracts.
Trials with any type of focus may be submitted (treatment, prevention, biomarker endpoints, supportive care, educational, and psychosocial endpoints).
What should be presented in the abstract and eventually in the poster is:
A brief background discussion
Trial design
Eligibility criteria
Specific aims
Statistical methods
Present accrual and target accrual
Contact information for people with a specific interest in the trial
Again, inclusion of preliminary or final trial results will disqualify an abstract in this category and is not allowed on the poster, though information on accrual to date or confirmation of feasibility is acceptable. Poster presentations in the Ongoing Clinical Trials category are not subject to SABCS pre-publication and embargo policies.
